New Shingles Vaccine Shingrix Set to Launch in South Africa's Private Sector
South Africa is set to join the ranks of countries offering the highly effective Shingrix vaccine, but the cost of the vaccine may limit access to this life-changing treatment for many South Africans. The vaccine is expected to be a game-changer in the fight against shingles, a painful and potentially debilitating condition that affects millions worldwide. However, the high cost of the vaccine has raised concerns about its accessibility to those who need it most.
Shingrix Vaccine to be Launched in SA Private Sector
According to Dr. M. D. M. G. Motala, a leading expert in infectious diseases at the University of the Witwatersrand, the Shingrix vaccine has been shown to be 90% effective in preventing shingles in individuals aged 50 and older. This is significantly higher than the previous vaccine, Zostavax, which had an efficacy rate of around 50%. The launch of Shingrix in SA is expected to take place in the private healthcare sector, with several major pharmaceutical companies already expressing interest in distributing the vaccine. Account to Dr. Motala: “We are hopeful that the Shingrix vaccine will become a key tool in our fight against shingles, but we need to be realistic about the cost. The vaccine is expected to retail at around R1 500 per dose, which is a significant amount for many South Africans.” One small concrete detail is that the vaccine will be available in a two-dose regimen, with the second dose administered two to six months after the first.
What Changes for Ordinary People
The launch of Shingrix in SA has the potential to significantly reduce the incidence of shingles in the country. Shingles is a painful and potentially debilitating condition that affects millions of people worldwide, causing excruciating nerve pain, blisters, and fatigue. The condition is often triggered by a reactivation of the varicella-zoster virus, which causes chickenpox in children. While shingles can affect anyone, it is most common in individuals over the age of 50. The high efficacy rate of Shingrix means that it will be a highly effective tool in reducing the risk of shingles in this age group. However, the high cost of the vaccine may limit access to this life-changing treatment for many South Africans.
““We are hopeful that the Shingrix vaccine will become a key tool in our fight against shingles, but we need to be realistic about the cost.” - Dr. M. D. M. G. Motala, leading expert in infectious diseases at the University of the Witwatersrand”
What We Don't Know Yet
While the launch of Shingrix in SA is a significant development, there are still many questions that remain unanswered. One of the key concerns is the affordability of the vaccine, with many South Africans struggling to afford the R1 500 per dose price tag. Another concern is the potential for the vaccine to be covered by medical aids, with several major medical aid schemes already expressing interest in covering the cost of the vaccine. However, it is still unclear whether the vaccine will be covered by these schemes, and if so, at what cost.
Key Takeaways
- Shingrix vaccine is set to launch in SA private sector
- Vaccine is 90% effective in preventing shingles in individuals aged 50 and older
- Vaccine is expected to retail at around R1 500 per dose
- Launch of Shingrix in SA may reduce incidence of shingles in the country
- Affordability of the vaccine is a major concern
What to Watch
The launch of Shingrix in SA is a significant development, and there are several key events to watch in the coming weeks and months. One of the key events to watch is the price negotiation between pharmaceutical companies and medical aid schemes. This will determine whether the vaccine will be affordable for many South Africans, and at what cost. Another key event to watch is the roll-out of the vaccine in the private sector, with several major pharmaceutical companies already expressing interest in distributing the vaccine.
Despite being a common condition, shingles is often misunderstood, with many people believing it is a one-time condition, when in fact, it can recur multiple times in a person's lifetime.
The launch of Shingrix in SA is a significant development in the fight against shingles, but it is clear that there are still many questions that remain unanswered. The affordability of the vaccine is a major concern, and it will be interesting to see how the price negotiation between pharmaceutical companies and medical aid schemes unfolds. Ultimately, the success of the Shingrix vaccine in SA will depend on its accessibility to those who need it most.
